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Th  e pilot observational study by Weber-Carstens and 
colleagues [1] provides important contributions to a 
mecha  nistic explanation of the puzzling and complex 
phenomena of ICU-acquired weakness (ICU-AW). Earlier 
ﬁ  ndings from this research group suggested that ICU-
AW is primarily a myopathy [2] and conﬁ  rmed that initial 
pathology manifests, on average, 7 days after ICU 
admission among the most severely ill [2-4]. In the 
current subanalysis with 40 of the original 52 subjects, 
multiple factors were examined for association with 
myopathy: molecular (IL-6, C-reactive protein (CRP), 
and insulin growth factor binding protein (IGFBP)-1); 
serum osmolarity; medication use (norepinepherine, 
dobu  tamine, hydrocortisone, aminoglycosides, analgesics, 
sedatives and neuromuscular blocking agents); and multi-
system factors (simpliﬁ  ed acute physiology (SAPS-2) and 
sequential organ failure assessment (SOFA) scores).
Th  e authors suggest systemic, inﬂ  ammatory-mediated 
pathology is the most signiﬁ  cant risk factor for ICU-AW. 
Th   e results on IL-6 show that its eﬀ  ects are actually quite 
modest. While IL-6 had a signiﬁ  cant contribution to the 
statistical model, the hazard ratio of 1.006 indicated a 
higher IL-6 (>230  picograms/ml) is little better than 
chance in predicting inexcitable muscle membranes (see 
Figure 7 in [1]). CRP, the second inﬂ  ammatory biomarker, 
was not associated with abnormal muscle excitability 
(P = 0.075). However, the sample size for this analysis was 
small. It may simply be that there are insuﬃ   cient 
numbers of results to derive a meaningful Cox regression 
equation - allowing a reasonable 10 samples per factor/
covariate, a sample size of 160 would provide more value 
to the statistical model (16 covariates; see Table 2 in [1]).
Th  e authors also report a hazard ratio for nor  epi-
nepherine similar to that for IL-6. Along with the relative 
diﬀ  erences in the presence of septic shock and organ 
dysfunction in Table 1 in [1] among participants with/
without inexcitable muscle membrane, this ﬁ  nding lends 
support to oxidative stress or the interaction of oxidative 
stress and pro-inﬂ  ammatory biomarkers as risk factors 
for myopathy in ICU patients [5]. Findings from this 
study illustrate the challenges of translating basic science 
to clinical settings. Multiple measures and more complex 
clinical data, such as a heterogeneous sample as in this 
report, make it diﬃ   cult to derive important conclusions 
from small samples.
Building a framework to identify ICU-AW early and to 
evaluate eﬃ   cacy of treatments is essential. Between 25 
and 50% of patients who receive mechanical ventilation 
for 7 or more days experience neuromuscular abnor-
malities and these abnormalities can result in weakness 
and impaired function years after discharge from the ICU 
[6]. In the United States, from 1997 to 2006, the number 
of ICU patients who received mechanical ventilation and 
were subsequently discharged to home has decreased 
while transfers to long-term acute care increased signiﬁ  -
cantly without concomitant changes in survival [7]. For 
older adults discharged with new or additional depen-
dency in daily activities after hospitalization, less than 
31% return to prehospital function [8]. Determining 
interventions that alter muscle pathology and associated 
dysfunction among patients who experience prolonged 
mechanical ventilation, whether from a mechanistic or a 
holistic perspective, has the potential to reduce the 
duration of mechanical ventilation and length of hospital 
stay [9].
Th  e role of IL-6 and other cytokines in muscle dys-
function is not yet clear. In healthy adults, very high 
levels can be myogenic after intense exercise [10]. Yet 
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[11]. Among patients with chronic inﬂ  ammatory 
conditions/diseases, serum IL-6 is related to muscle 
wasting and dysfunction [12]. In ICU patients, IL-6 can 
be unconnected to illness severity yet predictive of 
mortality [13,14]. Th  e sources of IL-6 - muscle versus 
leukocyte - may also be important to muscle pathology.
Developing understanding of basic pathology and 
establishing predictive biomarkers will provide the 
oppor  tunity for new hypothesis testing. In this explora-
tory report of risk factors associated with abnormal 
responses to direct muscle stimulation, molecular to 
multisystem levels of covariates were examined [1]. 
Future studies will be more compelling when focused on 
single-level, inter-related pathways. Investigations related 
to molecular cascade interactions are providing insight 
into the genetic, signaling, bioenergetic, and metabolic 
processes that contribute to muscle health and disease. 
Understanding of molecular determinants of common 
diseases encountered in the critically ill can provide the 
rationale for selection of therapeutic targets [15]. If a 
serum IL-6 value >230 picograms/ml is conﬁ  rmed  in 
future studies as an early indicator of muscle dysfunction, 
then the eﬃ   cacy of prevention and treatment strategies 
may be measured rapidly and inexpensively by IL-6.
Observational data like this report provide important 
information with which to calculate eﬀ  ect size and deter-
mine promising biologic pathways for future investiga-
tions. Results also suggest that the timing of interventions 
to prevent ICU-AW may need to occur earlier than 
typically occurs in many settings as serum IL-6 and 
muscle stimulation responses were abnormal quite early 
in the majority of patients who went on to manifest 
ICU-AW.
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